Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 9/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322566 | 1.00 | POLB (0.42) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL2325765 | 0.92 | LMNA (0.44) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL2323036 | 0.91 | LMNA (0.36) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL2321484 | 0.91 | LMNA (0.36) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL2325098 | 0.86 | RORC (0.40) | SMN1; SMN2ALDH1A1MEN1KMT2ARORC | |
| SCHEMBL2324646 | 0.86 | RORC (0.40) | SMN1; SMN2ALDH1A1MEN1KMT2ARORC | |
| SCHEMBL2332653 | 0.84 | RORC (0.38) | CYP3A4RORC | |
| SCHEMBL2325143 | 0.84 | KDM4E (0.39) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2324958 | 0.82 | RORC (0.34) | RORC | |
| SCHEMBL2324843 | 0.82 | MEN1 (0.40) | SMN1; SMN2ALDH1A1MEN1KMT2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | claimed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | POLB 2698/4885SMN1; SMN2 2843/4885LMNA 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.